SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rebound is being linked by traders to Morgan Stanley naming it a top pick on AWS growth and AI prospects, as well as AWS making its Trainium chips easier for developers to use. Bulls welcome the move and point to cloud and AI momentum, while skeptics question whether it can hold amid heavy capex and recent volatility.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the case for an FDA resubmission, though approval remains ahead and dizziness incidence has drawn some concern. Traders are broadly bullish on the trial result, with discussion also focused on short-covering and whether the rally can hold.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp selloff and break below technical support, with traders pointing to disclosed insider selling and a DBS downgrade as possible pressures. The community is divided between expecting further declines and viewing the pullback as a buying opportunity, while some also cite weakness in Indonesian markets and broader regional macro concerns.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third quarter and an upbeat 2027 EBITDA outlook are driving CLFs rally, with bullish traders anticipating short covering. Others warn the outlook depends on steel prices and remain focused on the companys debt, while some see the move as a sell-the-news bounce.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios FDA expansion of Anktiva plus BCG to papillary-only bladder cancer, alongside positive long-term trial data, is the main focus. The share-price decline despite those developments has prompted debate over profit-taking, broader biotech weakness and options activity, while some traders allege manipulation without substantiation.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors raised Q3 growth outlook, driven by royalties from its Vertical Power Delivery licensing, is fueling positioning ahead of its earnings report. Traders are split between viewing the pullback despite stronger guidance and AI-power demand as an opportunity and worrying that volatility and high expectations could leave room for further weakness.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing insider share sales and upcoming lockup releases as added supply pressure alongside concerns about valuation, growth and its OpenAI exposure. Bears warn of further downside, while bulls argue the decline is overdone and are buying the dip; some also attribute weakness to a broader AI and semiconductor-sector retreat.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported takeover interest from Lundbeck is driving speculation about a potential bid or bidding war and heightened trading activity. Xeris has said it is not for sale, leaving traders divided between treating the chatter as a credible deal catalyst and focusing on Recorlev growth and XP-8121s pipeline prospects.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a persistent selloff and weak solar-sector sentiment, with traders pointing to interest-rate sensitivity, policy and financing concerns, and analyst target cuts. The debate is whether its AI data-center, battery-storage and virtual-power-plant initiativesand perceived high short interestcould offset those pressures; some traders view them as a potential turnaround catalyst, while others remain bearish.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is drawing attention around its MSToronto multiple-sclerosis presentations, especially initial Phase 1 azer-cel findings in progressive MS and additional BRIUMVI data. Traders are hopeful the readouts and coming BRIUMVI milestones could support growth, while others are frustrated by choppy trading; buyout talk remains speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ABVX is drawing attention over a sharp pullback and the lack of a confirmed buyout, with traders pointing to a long wait for Crohns data as a potential overhang. Some blame broader biotech weakness and rising rates and expect continued volatility, while others view the decline as a buying opportunity based on obefazimods UC prospects and continued M&A speculation.

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.read more...

Earnings Scheduled For September 21, 2026

Companies Reporting Before The Bell
 Ennis (NYSE:EBF) is expected to report earnings for its second quarter.
Companies Reporting After The Bell
 Abivax (NASDAQ:ABVX) is projected to report quarterly loss at $1.08 perread more...

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

Stocks in focus: Abivax, Marygold and Neuphoria report losses; Accenture partners with Anthropic, while Lobo Technologies posts H1 growth.read more...

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abivax will report H1 earnings Sept. 21; analysts expect a $1.08 loss/share and $1.86M revenue.read more...

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds 

Abivax said underwriters have fully exercised their option to purchase an additional 960,000 American depositary shares as part of their $920 million offering.

Abivax Prices $800M Offering Of ADS – Here’s A Look At Some Key Figures

The size of the offering was increased to $800 million from the previously announced offering of $600 million in ADSs.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Bearish Sentiment

<ul class="summary-bullets"><li>TRAX plans to release top-line data from the first ANB033 celiac-disease study cohort on Monday.</li><li>CYTK will present additional Aficamten analyses at HFSA, while EPRX presents previously disclosed EP-104GI data at ACG.</li><li>ARWR and VSTM have clinical updates scheduled for Wednesday on Alzheimer’s research and the cancer drug VS-7375.</li></ul><p>Biotech investors face a packed week, with First Tracks set to report early data on a celiac-disease drug, Verastem preparing an update on a cancer treatment, and the FDA approaching decisions on two eye therapies.</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> gained 2.8% last week, outperforming&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a>, up 1.2%, and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, up 0.2%. The&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> rose 0.6%, trailing SPY but beating QQQ, while the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 0.4%.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_d7c3a475bc.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.12</td><td>TRAX</td><td>First Tracks plans to report Cohort 1 top-line data for ANB033 in celiac disease; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.12</td><td>CYTK / HFSA</td><td>Two late-breaking analyses of Aficamten in nonobstructive hypertrophic cardiomyopathy at the HFSA meeting</td></tr><tr><td>Oct.12</td><td>EPRX / ACG</td><td>Poster on EP-104GI and dysphagia improvements through 52 weeks in the RESOLVE study</td></tr><tr><td>Oct.13</td><td>JNJ</td><td>Third-quarter results; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.14</td><td>ARWR</td><td>Webinar with interim clinical data from the ARO-MAPT study in Alzheimer’s disease and other tauopathies</td></tr><tr><td>Oct.14</td><td>VSTM</td><td>Investor event with initial efficacy and updated safety data for VS-7375</td></tr><tr><td>Oct.14-Oct.17</td><td>PHAR / ESID</td><td>Late-breaking presentation of Phase 2 Leniolisib data in primary immunodeficiencies with immune dysregulation</td></tr><tr><td>Oct.15</td><td>RHHBY</td><td>FDA target action date for Roche’s Enspryng in thyroid eye disease</td></tr><tr><td>Oct.17</td><td>VTRS / IRD</td><td>FDA target action date for phentolamine ophthalmic solution 0.75% in presbyopia</td></tr><tr><td>Oct.17-Oct.20</td><td>UEG Week</td><td>Gastroenterology conference in Barcelona, with presentations from EPRX, ABVX, Agomab and PALI</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Monday: TRAX, CYTK and EPRX</strong></h2><p>First Tracks Biotherapeutics plans to report top-line data on Monday from Cohort 1 of its Phase 1b study of ANB033, a drug that blocks the immune target CD122. The gluten-challenge study is testing whether the drug can protect the intestinal lining from damage in people with celiac disease.&nbsp;</p><p>Cytokinetics (CYTK) will present two late-breaking analyses of Aficamten on Monday at the Heart Failure Society of America’s meeting in Phoenix. The ACACIA-HCM analyses examine the drug’s overall effectiveness and impact on exercise performance in nonobstructive hypertrophic cardiomyopathy, where a thickened heart muscle does not block blood flow. The company plans to submit a supplemental new drug application in the fourth quarter.&nbsp;</p><p>Eupraxia Pharmaceuticals (EPRX) will present a poster on Monday at the American College of Gastroenterology meeting on EP-104GI in eosinophilic esophagitis, an inflammatory condition of the esophagus. It will examine improvements in difficulty swallowing that lasted up to 52 weeks in the Phase 1b/2 Resolve study. Eupraxia reported the 52-week results from its highest-dose group late last month.&nbsp;</p><h2 class="st-heading-2"><strong>Midweek: JNJ, ARWR And VSTM</strong></h2><p>Johnson &amp; Johnson (JNJ) will report its third-quarter results on Tuesday. According to Koyfin, analysts expect revenue of $25.38 billion, up 0.3%. They forecast earnings before interest, taxes, depreciation and amortization (EBITDA) at $8.24 billion, down 8%, and earnings before interest and taxes (EBIT) at $7.42 billion, down 10%. GAAP earnings per share (EPS) are projected at $2.07, down 9%.</p><p>On Wednesday, Arrowhead Pharmaceuticals (ARWR) will share interim results from an early-stage study of ARO-MAPT, its treatment for Alzheimer’s disease and other disorders linked to abnormal tau protein. A webinar on the same day will also include an update on the company’s central nervous system pipeline.</p><p>Verastem Oncology (VSTM) will host an investor event on Wednesday to present initial efficacy results and updated safety data for VS-7375. The oral drug targets KRAS G12D, a cancer-driving mutation, and is being studied in pancreatic, lung and colorectal cancers as part of the Target-D program.</p><h2 class="st-heading-2"><strong>FDA Target Dates Loom For 2 Eye Treatments</strong></h2><p>Roche (RHHBY) is awaiting an FDA decision by Thursday on its application to use Enspryng (Satralizumab) to treat thyroid eye disease. The application received Priority Review. If approved, Roche says Enspryng could become the first at-home, under-the-skin treatment for the condition. The Phase 3 SatraGO results were presented last year.</p><p>Viatris (VTRS) and Opus Genetics (IRD) face an Oct.17 FDA target date for phentolamine eye drops, also known as MR-141, as a treatment for presbyopia — the age-related difficulty focusing on nearby objects. The FDA accepted the application seeking approval for this new use.</p><h2 class="st-heading-2"><strong>GI Conferences Bring More Data Presentations</strong></h2><p>Pharming (PHAR) will present previously announced Phase 2 results for Leniolisib at the European Society for Immunodeficiencies meeting, running Oct.14-Oct.17 in the Netherlands. The study involved patients with rare, genetically defined immune disorders. Pharming released the top-line findings last month.&nbsp;</p><p>Meanwhile, the United European Gastroenterology Week runs from Oct.17-Oct.20 in Barcelona. Abivax (ABVX) will present seven Obefazimod abstracts, including results from a Phase 3 maintenance study and patient subgroup analyses, longer-term Phase 2 findings and a preclinical study.</p><p>Agomab will present long-term data from an extension of its STENOVA Phase 2a study, in which patients continued Ontunisertib treatment for up to 60 weeks. The study focuses on fibrostenosing Crohn’s disease, which can cause narrowing of the bowel. Palisade Bio (PALI) will make four presentations on PALI-2108, including Phase 1b findings on early clinical improvements and evidence that the drug affects PDE4, a protein involved in inflammation. Three additional posters will cover gut-targeted delivery, safety and potential biomarkers that could help predict treatment response.</p><p>Separately, Filana Therapeutics (FLNA) said it will attend the Maxim Growth Summit, running Oct.12-Oct.14, for one-on-one meetings.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-big-pharma-buyout-booth-ash/cZx4tMpRBF7">SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&amp;A Negotiation Lounge' Booth At ASH&nbsp;</a></p>

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Arrowhead Pharmaceuticals Inc.

Cytokinetics Inc

Eupraxia Pharmaceuticals Inc

Filana Therapeutics Inc

iShares Biotechnology ETF

Opus Genetics Inc.

Johnson & Johnson

Palisade Bio Inc

Pharming Group

Roche Holdings AG ADR

First Tracks Biotherapeutics Inc.

Verastem Inc

Viatris Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are closely tracking Phase 3 trial presentations and upcoming FDA NDA filing milestones for potential upside.

Market sentiment remains divided as shares test recent lows, sparking fierce debate on whether to accumulate now or wait for a reversal.

Current Price	$87.89
Prev Close	$88.13
Open	$88.04
Dividend Yield	0.00%
50-Day Moving Average	$106.91
Beta	0.87
Avg. Volume	1.37M
PE Ratio	-14.44

52-Week High	$148.83
52-Week Low	$69.81
Market Capitalization	$7.71B
EPS (Annual)	-$5.46
Price to Book	16.80
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABVX Fundamentals